Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids

• Published in: Burns Vol. 40; no. 4; pp. 583 - 588
• Main Authors: Ahuja, Rajeev B, Chatterjee, Pallab
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.06.2014
• Subjects: Adolescent; Adult; Calcium Channel Blockers - therapeutic use; Cicatrix, Hypertrophic - drug therapy; Critical Care; Female; Glucocorticoids - therapeutic use; Humans; Hypertrophic scars; Injections, Intralesional; Kaplan-Meier Estimate; Keloid - drug therapy; Keloids; Male; Middle Aged; Treatment Outcome; Triamcinolone; Triamcinolone Acetonide - therapeutic use; Vancouver Scar Scale; Verapamil; Verapamil - therapeutic use; Young Adult; Keloids; Verapamil; Vancouver Scar Scale; Triamcinolone; Hypertrophic scars
• ISSN: 0305-4179; 1879-1409
• DOI: 10.1016/j.burns.2013.09.029

Abstract There is not much level 1 evidence based literature to guide management of hypertrophic scars and keloids despite an array of therapeutic modalities at disposal. Intralesional (i/l) triamcinolone injections have remained a gold standard in non surgical management. Sporadic reports on use of i/l verapamil suggest its efficacy. Since verapamil has not found sufficient mention as an effective alternative modality, it was decided to undertake a randomized study which could also address some additional clinical parameters. A randomized, parallel group and observer blinded comparison with 40 patients (48 scars) was carried out to compare the effects of i/l triamcinolone (T) (22 scars) and verapamil injections (V) (26 scars). 1.5 ml was the maximum indicative volume decided in the study protocol for both the drugs (triamcinolone @40 mg/ml and verapamil @ 2.5 mg/ml). Patients included were aged between 15–60 years with scars ranging between 0.5–5 cm (but total area roughly <6 cm2 ), and scars under 2 years duration. Patients with keloidal diathesis were excluded. Injections were scheduled every three weeks until complete flattening of the scar or eight sessions, which ever came earlier. No concomitant therapies like massage, silicone gel or pressure garments were used. Scar evaluation at each stage was done by serial photographic records as well as by Vancouver Scar Scale (VSS). Comparative survival analysis between the two drugs was done using Kaplan Meier curves, and VSS scores were analyzed using Wilcoxon test and log rank test. Mean zero VSS scores were achieved with treatments in respect of scar height (T-12 weeks, V-21 weeks), vascularity (T-15 weeks, V-18 weeks) and pliability (T-15 weeks, V-21 weeks). The improvement in scar vascularity and pliability kept pace with decrease in scar height, in both the groups. There was not much difference in the rate of change of scar pigmentation with either drug but almost 60% patients in both the groups regained normal pigmentation. Our study adds to evidence of verapamil's capability in flattening the raised scars. With an extremely low cost and fewer adverse effects it deserves better positioning in the wide armamentarium against hypertrophic scars. It also offers several therapeutic possibilities to alternate with triamcinolone or be used simultaneously in larger (or multiple) scars.